logo

Windtree Therapeutics Inc. (WINT)



Trade WINT now with
  Date
  Headline
7/1/2021 7:32:08 AM Windtree Appoints Diane Carman As SVP And General Counsel
5/13/2021 8:18:25 AM Windtree Therapeutics Q1 Net Loss $9.0 Mln Or $0.51/Shr Vs Loss Net Loss $6.5 Mln Or $0.48/Shr Last Year
4/19/2021 7:28:22 AM Windtree Therapeutics Announces New Istaroxime Expedited Review Filing Of Patent
3/25/2021 4:19:39 PM Windtree Therapeutics Closes $30 Mln Public Offering
3/23/2021 8:35:13 AM Windtree Therapeutics Announces Pricing Of $30.0 Mln Public Offering
2/16/2021 7:19:33 AM Windtree Unveils Issuance Of New U.S. Patent Covering Technology On Its Redesigned AEROSURF Device
1/6/2021 8:17:02 AM Windtree Doses First Patient In Its Phase 2 Clinical Trial Studying Lucinactant
10/1/2020 7:41:06 AM Windtree : First Patient Dosed In Phase 2 Study Of Istaroxime For Acute Treatment Of Early Cardiogenic Shock
9/29/2020 7:34:55 AM Windtree: FDA Accepts IND Application For Phase 2 Clinical Trial Of KL4 Surfactant In Acute Lung Injury With COVID-19
7/20/2020 7:04:47 AM Windtree Therapeutics Names John Hamill SVP, CFO
5/20/2020 8:32:01 AM Windtree Therapeutics Announces Pricing Of 2.76 Mln Units At $7.25/Unit
4/29/2020 7:47:06 AM Windtree Says First Patient Enrolled In AEROSURF Bridging Study For Treatment Of Respiratory Distress Syndrome
3/31/2020 7:50:35 AM Windtree Enters Deal With Lee's Pharma For Non-Dilutive Funding Of The Continued Development Of AEROSURF
3/24/2020 7:47:11 AM Windtree To Study Proprietary KL4 Surfactant To Potentially Mitigate Pulmonary Effects Of Severe COVID-19 Infection